Peer-reviewed veterinary case report
Interleukin-2 injection after nerve tumor surgery in dogs showed no
By Haagsman, Annika N et al.·Published in BMC veterinary research·2013·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.
- Species:
- dog
Plain-English summary
A group of dogs with peripheral nerve sheath tumors underwent surgery to remove the tumors, with some receiving an injection of interleukin-2 during the procedure while others received a placebo. After the surgery, there was no significant difference in survival rates between the two groups, although dogs operated on by specialist-certified surgeons had longer survival times overall. The study found that while the surgery itself led to a long survival time, the additional treatment with interleukin-2 did not improve outcomes.
People also search for: dog nerve sheath tumor treatment · interleukin-2 for dogs · dog tumor surgery recovery · canine tumor survival rates
Abstract
BACKGROUND: The objective of this study was to evaluate the effect on outcomes of intraoperative recombinant human interleukin-2 injection after surgical resection of peripheral nerve sheath tumours. In this double-blind trial, 40 patients due to undergo surgical excision (<5 mm margins) of presumed peripheral nerve sheath tumours were randomized to receive intraoperative injection of interleukin-2 or placebo into the wound bed. RESULTS: There were no significant differences in any variable investigated or in median survival between the two groups. The median recurrence free interval was 874 days (range 48-2141 days), The recurrence-free interval and overall survival time were significantly longer in dogs that undergone the primary surgery by a specialist-certified surgeon compared to a referring veterinarian regardless of whether additional adjunct therapy was given. CONCLUSION: Overall, marginal excision of peripheral nerve sheath tumours in dogs resulted in a long survival time, but adjuvant treatment with recombinant human interleukin-2 (rhIL-2) did not provide a survival advantage.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23927575/